TheStreet Ratings team reiterated 3 stocks with a buy rating on Friday
Will Kroger make a play for Safeway? Cramer's on the fence, but he does think Gilead Sciences is suffering from investor withdrawal from the biotech sector as a whole.
4:15 pm Merck's investigational hepatitis C treatment regimen MK-5172/MK-8742 shows robust anti-HCV activity in HIV/HCV co-infected patients with HCV Genotype 1 infectionYahoo 03/06 16:15 ET
Bristol-Myers' BMS-663068 fared well in a mid stage study.
Alnylam Announces Closing of Previously Announced Acquisition of Merck’s Sirna Therapeutics Subsidiarynoodls 03/06 09:53 ET
Alnylam Announces Closing of Previously Announced Acquisition of Merck's Sirna Therapeutics Subsidiary CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a ...
Merck’s Consumer Health Division Breaks $1bn Barrier Through Transition of Neurobion and Floratil Brands from Merck SeronoBusiness Wire 03/06 08:00 ET
DARMSTADT, Germany--(BUSINESSWIRE)-- Merck’s Consumer Health division has significantly increased in size following its incorporation of Neurobion®, a leading global brand in the vitamin B segment, and Floratil®, a leading brand in Brazil in the probiotic antidiarrheal segment, from the Merck Serono division. The additions increase annual sales of Consumer Health by approximately 55% to over $1 billion (> € 740 million). Floratil and Neurobion; “The inclusion of the Neurobion and Floratil brands into Consumer Health will further strengthen our presence in emerging markets and add two leading brands to our portfolio.